# Galderma R&D: Phase 3 study started recruiting, 240 planned (Atopic Dermatitis)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Galderma R&D |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis |
| NCT ID | NCT07762833 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Atopic Dermatitis |
| Intervention types | biological, other |
| Target enrollment | 240 |
| Site countries | China |
| Posted | 2026-08-13 |
| Planned start | 2026-10-08 |
| Event | Started recruiting |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-16 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 240 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07762833). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.